SCHEMBL18397886

SCHEMBL18397886

NCc1cc(=O)c2ccc(-c3cn(-c4ccccc4)nn3)cc2o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 3/20 0.53
▸ KEAP1 Q14145 1/20 0.43
▸ NFE2L2 Q16236 1/20 0.43
▸ CDC7 O00311 1/20 0.42
▸ MAOA P21397 1/20 0.41
▸ NOTUM Q6P988 1/20 0.41
▸ PTGS2 P35354 2/20 0.40
▸ CA1 P00915 2/20 0.40
▸ CA2 P00918 2/20 0.40
▸ CA5A P35218 2/20 0.40
▸ CA5B Q9Y2D0 2/20 0.40
▸ CA12 O43570 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ PIK3CA P42336 1/20 0.39
▸ HDAC3 O15379 3/20 0.38
▸ HDAC1 Q13547 2/20 0.38
▸ HDAC2 Q92769 2/20 0.38
▸ HDAC10 Q969S8 2/20 0.38
▸ HDAC8 Q9BY41 2/20 0.38
▸ HDAC6 Q9UBN7 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18397934 0.99 LOXL2 (0.54) LOXL2KEAP1NFE2L2CDC7MAOA
SCHEMBL18397854 0.91 LOXL2 (0.63) LOXL2KEAP1NFE2L2CDC7MAOA
Hydrochloric Acid SCHEMBL18397863 0.90 LOXL2 (0.65) LOXL2KEAP1NFE2L2CDC7MAOA
SCHEMBL18397944 0.85 EGLN1 (0.42) LOXL2KEAP1NFE2L2CDC7CA1
SCHEMBL18397879 0.82 LOXL2 (0.59) LOXL2
Hydrochloric Acid SCHEMBL18397950 0.81 LOXL2 (0.61) LOXL2
SCHEMBL20438101 0.79 P2RY14 (0.43) CA1CA2CA12CA9HDAC3
SCHEMBL18397954 0.79 CA12 (0.63) PTGS2CA1CA2CA12CA9
Hydrochloric Acid SCHEMBL18397877 0.78 CA12 (0.62) LOXL2CA1CA2CA12CA9
SCHEMBL18397952 0.77 LOXL2 (0.49) LOXL2KEAP1NFE2L2CDC7HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180215727-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2018-08-02 — — US claimed
EP-3325462-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF Pharmakea, Inc. (US) 2018-05-30 — — EP claimed
WO-2017015221-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2017-01-26 — — WO claimed
EP-3510404-A1 CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF Pharmakea, Inc. (US) 2019-07-17 — — EP disclosed
US-20190192697-A1 CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF PHARMAKEA, INC. 2019-06-27 — — US disclosed
US-20180215727-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2018-08-02 — — US disclosed
US-20180215727-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2018-08-02 — — US disclosed
EP-3325462-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF Pharmakea, Inc. (US) 2018-05-30 — — EP disclosed
WO-2018048928-A1 CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF PHARMAKEA, INC. (US) 2018-03-15 — — WO disclosed
WO-2017197088-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS PHARMAKEA, INC. (US) 2017-11-16 — — WO disclosed
WO-2017015221-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2017-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215727-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX LOXL2 1/4885KEAP1 940/4885NFE2L2 530/4885
US-20190192697-A1 CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF LOXL2, LOXL1, LOXL3 LOXL2 1/4885KEAP1 410/4885NFE2L2 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback